Actinium-225 compositions of matter and methods of their use

Patent metadata

Field	Value
Publication number	US-9555140-B2
Application number	US-201414507094-A
Country	US
Kind code	B2
Filing date	Oct 6, 2014
Priority date	Oct 7, 2013
Publication date	Jan 31, 2017
Grant date	Jan 31, 2017

Abstract

The present invention is directed to improved methods for generating compositions comprising actinium-225.

First claim

What is claimed:

1. An actinium-225 composition, comprising the following quotient of activity quantity ratios:
actinium-226/actinium-225 less than 25;
actinium-227/actinium-225 less than 0.02;
cerium-139/actinium-225 less than 0.1;
cerium-141/actinium-225 less than 20;
cerium-143/actinium-225 less than 70; and
lanthanum-140/actinium-225 less than 20
wherein the quotient of activity quantity ratios are measured at the end of bombardment.

2. The actinium-225 composition of claim 1 , wherein the quotient of activity quantity ratios are:
actinium-226/actinium-225 between 0.2 and 25;
actinium-227/actinium-225 between 0.0001 and 0.02;
cerium-139/actinium-225 between 0.001 and 0.1;
cerium-141/actinium-225 between 0.03 and 20;
cerium-143/actinium-225 between 0.1 and 70; and
lanthanum-140/actinium-225 between 0.03 and 20.

3. The actinium-225 composition of claim 1 , wherein the quotient of activity quantity ratios are:
actinium-226/actinium-225 less than 8;
actinium-227/actinium-225 less than 0.01;
cerium-139/actinium-225 less than 0.05;
cerium-141/actinium-225 less than 6;
cerium-143/actinium-225 less than 20; and
lanthanum-140/actinium-225 less than 6.

4. The actinium-225 composition of claim 1 , wherein the quotient of activity quantity ratios are:
actinium-226/actinium-225 between 0.64 and 8;
actinium-227/actinium-225 between 0.0005 and 0.01;
cerium-139/actinium-225 between 0.005 and 0.05;
cerium-141/actinium-225 between 0.1 and 6;
cerium-143/actinium-225 between 0.3 and 20; and
lanthanum-140/actinium-225 between 0.1 and 6.

5. An actinium-225 composition comprising the following quotient of activity quantity ratios:
actinium-226/actinium-225 less than 1;
actinium-227/actinium-225 less than 0.03;
cerium-139/actinium-225 less than 0.3;
cerium-141/actinium-225 less than 30;
cerium-143/actinium-225 less than 1; and
lanthanum-140/actinium-225 less than 1.

6. The actinium-225 composition of claim 5 , wherein the quotient of activity quantity ratios are:
actinium-226/actinium-225 less than 0.05;
actinium-227/actinium-225 less than 0.01;
cerium-139/actinium-225 less than 0.01;
cerium-141/actinium-225 less than 10;
cerium-143/actinium-225 less than 0.3; and
lanthanum-140/actinium-225 less than 0.3.

7. The actinium-225 composition of claim 5 , wherein the quotient of activity quantity ratios are:
actinium-226/actinium-225 between 0.001 and 10; and
actinium-227/actinium-225 between 0.0003 and 0.03.

8. The actinium-225 composition of claim 5 , wherein the quotient of activity quantity ratios are:
actinium-226/actinium-225 between 0.005 and 0.05; and
actinium-227/actinium-225 between 0.001 and 0.01.

9. A pharmaceutical composition comprising the actinium-225 composition of claim 5 and a pharmaceutically acceptable carrier.

10. The pharmaceutical composition of claim 9 , wherein the actinium-225 is conjugated to an antibody.

11. A method of treating cancer in a patient comprising administering to the patient the pharmaceutical composition of claim 9 .

12. The method of claim 11 , wherein the cancer is breast cancer, a leukemia, a lymphoma, brain cancer, liver cancer, lung cancer, melanoma, ovarian cancer, prostate cancer, pancreatic cancer, or bone cancer.

Assignees

• Los Alamos Nat Security Llc

Inventors

• Birnbaum Eva Rachel
• Engle Jonathan W
• Nortier Francois Meiring

Classifications

• A61K51/00 Primary

  Preparations containing radioactive substances for use in therapy or testing in vivo · CPC title

• A61K51/1093 Primary

  conjugates with carriers being antibodies · CPC title